CryoPort (OTCBB: CYRX) Adds Veteran Biopharmaceutical Executive to Management Team

CryoPort Inc. CYRX, a provider of technology-driven transport and packaging systems focused on helping companies similar to Life Technologies Corp. LIFE and Pfizer Inc. PFE, recently added veteran biopharmaceutical executive, Mark Engelhart, to its management team as Senior Vice President and Chief Commercial Officer.

CryoPort, Inc. CYRX announces the addition of Mark Engelhart to the management team as Senior Vice President and Chief Commercial Officer. Mr. Engelhart has over 28 years experience within the pharmaceutical, clinical development, and life sciences industries, with companies such as Bayer Pharmaceuticals, Abbott Labs, Covance, and Quest Diagnostics. Mr Engelhart brings to CryoPort experience and leadership in building commercial organizations, defining product development and strategy, and general management.  His prior experiences cross the spectrum of biopharmaceutical development, from pre-clinical and clinical development through post approval sales and marketing.

“Experienced leadership on the commercial front is imperative for our success,” said Larry Stambaugh, CryoPort's Chairman and Chief Executive Officer.  “We are building both a direct sales organization and working with our channel partners like FedEx®, so having a hands-on CCO with industry experience to drive both customer and partner relationships is key.”

CryoPort offers the CryoPort Express® service directly to pharmaceutical and other life science companies shipping biological substances as a replacement for the use hazardous dry ice and costs of using specialty couriers.  Additionally, CryoPort has partnered with FedEx® to provide the CryoPort Express® dry shipper as part of their Temperature Controlled Solutions offering.

About CryoPort, Inc.

CryoPort (www.cryoport.com) has developed a leading edge, proprietary, technology-driven transport and packaging system focused on providing a solution that replaces dry ice for the frozen shipping market in the growing global life science industry. The products developed by CryoPort have a 10+ day holding time, are using “green” materials and are essential components of the infrastructure required for the testing, research and end-user delivery of temperature-sensitive medicines and biomaterials in an increasingly complex global logistical environment.

Forward Looking Statements

Statements in this press release which are not purely historical, including statementsregarding CryoPort, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2010. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. CryoPort, Inc. disclaims any obligation, and does not undertake toupdate or revise any forward-looking statements in this press release.